Profile data is unavailable for this security.
About the company
Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. It is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The Company is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). It has created over 1,000 novel psychedelic molecular compounds and derivatives.
- Revenue in USD (TTM)0.00
- Net income in USD-15.11m
- Incorporated1994
- Employees7.00
- LocationEnveric Biosciences Inc4851 Tamiami Trail N, Suite 200NAPLES 34103United StatesUSA
- Phone+1 (239) 302-1707
- Fax+1 (732) 243-9254
- Websitehttps://www.enveric.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lixte Biotechnology Holdings Inc | 0.00 | -4.69m | 5.68m | 3.00 | -- | -- | -- | -- | -2.38 | -2.38 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -118.45 | -104.18 | -130.17 | -111.05 | -- | -- | -- | -- | -- | -1,253.20 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| Galera Therapeutics Inc | 0.00 | -45.75m | 5.82m | 7.00 | -- | -- | -- | -- | -0.9971 | -0.9971 | 0.00 | -2.48 | 0.00 | -- | -- | 0.00 | -115.30 | -83.69 | -142.79 | -97.54 | -- | -- | -- | -- | -- | -6.49 | 9.23 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
| Creative Medical Technology Holdings Inc | 9.00k | -5.28m | 5.82m | 4.00 | -- | 0.6341 | -- | 647.10 | -3.74 | -3.74 | 0.0064 | 6.81 | 0.0007 | 0.4291 | -- | 2,250.00 | -42.47 | -110.00 | -43.88 | -- | 60.00 | 65.82 | -58,624.33 | -7,961.14 | 23.53 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| AiXin Life International Inc | 4.09m | -2.09m | 5.82m | 207.00 | -- | -- | -- | 1.42 | -0.0836 | -0.0836 | 0.1636 | -0.0765 | 0.8268 | 5.43 | 10.02 | 19,757.49 | -42.27 | -16.93 | -- | -34.54 | 16.25 | 48.13 | -51.12 | -36.96 | 0.1515 | -- | -- | -- | 51.00 | 58.08 | 67.18 | -- | 194.59 | -- |
| Mystic Holdings Inc | -100.00bn | -100.00bn | 5.90m | 79.00 | -- | 0.2422 | -- | -- | -- | -- | -- | 0.2155 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.2228 | -- | 0.1849 | -- | 199.82 | -- | 34.32 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -16.10m | 5.94m | 8.00 | -- | 0.2985 | -- | -- | -14.03 | -14.17 | 0.00 | 19.06 | 0.00 | -- | -- | 0.00 | -49.97 | -- | -53.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| Virios Therapeutics Inc | 0.00 | -5.07m | 6.00m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| TFF Pharmaceuticals Inc | 885.71k | -19.93m | 6.00m | 19.00 | -- | 0.9205 | -- | 6.78 | -10.20 | -10.20 | 0.4371 | 2.11 | 0.0647 | -- | 3.72 | 46,616.32 | -145.46 | -79.57 | -181.57 | -83.41 | -- | -- | -2,249.83 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
| Enveric Biosciences Inc | 0.00 | -15.11m | 6.05m | 7.00 | -- | 0.8777 | -- | -- | -6.46 | -6.46 | 0.00 | 0.8887 | 0.00 | -- | -- | 0.00 | -122.02 | -104.94 | -178.49 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| Titan Pharmaceuticals Inc | 87.00k | -4.95m | 6.07m | 4.00 | -- | 0.997 | -- | 69.75 | -6.41 | -6.41 | 0.1119 | 6.66 | 0.0197 | -- | 1.23 | 21,750.00 | -112.41 | -96.80 | -170.59 | -156.65 | -- | -- | -5,694.25 | -406.26 | -- | -415.19 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| Applied DNA Sciences Inc | 5.52m | -12.50m | 6.09m | 53.00 | -- | -- | -- | 1.10 | -17.13 | -17.13 | 7.67 | -0.0558 | 0.3893 | 10.38 | 4.64 | 104,110.80 | -87.15 | -88.57 | -111.09 | -121.91 | 33.98 | 44.35 | -223.89 | -113.26 | 1.54 | -- | -- | -- | -26.43 | 27.92 | -18.73 | -- | 33.80 | -- |
| Genprex Inc | 0.00 | -27.63m | 6.11m | 26.00 | -- | 0.6389 | -- | -- | -19.18 | -19.18 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -153.97 | -92.06 | -202.83 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| Xenetic Biosciences Inc | 2.44m | -4.47m | 6.20m | 4.00 | -- | 0.7145 | -- | 2.54 | -2.92 | -2.92 | 1.59 | 5.63 | 0.2116 | -- | -- | 611,240.00 | -38.71 | -48.91 | -41.54 | -52.82 | -- | -- | -182.95 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
| Reliv International Inc | 35.13m | -175.48k | 6.35m | 208.00 | -- | 0.9165 | 15.88 | 0.1808 | -0.1005 | -0.1005 | 20.12 | 6.55 | 2.09 | 8.02 | 228.49 | -- | -1.05 | -4.65 | -1.47 | -6.06 | 40.90 | 41.98 | -0.4996 | -2.33 | 1.07 | -- | 0.1064 | -- | -2.94 | -9.37 | 76.65 | -- | -35.85 | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -38.52m | 6.38m | 22.00 | -- | 1.09 | -- | -- | -9.49 | -9.49 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -117.64 | -61.43 | -145.05 | -68.82 | -- | -- | -- | -- | -- | -3,240.31 | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to Enveric Biosciences Inc's reporting currency: US Dollar USD
6.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AdvisorShares Investments LLCas of 31 Mar 2024 | 238.83k | 3.27% |
| HRT Financial LLCas of 31 Mar 2024 | 63.03k | 0.86% |
| Citadel Securities LLCas of 31 Mar 2024 | 40.10k | 0.55% |
| Virtu Americas LLCas of 31 Mar 2024 | 33.84k | 0.46% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 29.58k | 0.41% |
| G1 Execution Services LLCas of 31 Mar 2024 | 18.25k | 0.25% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 18.20k | 0.25% |
| Two Sigma Investments LPas of 31 Mar 2024 | 15.40k | 0.21% |
| Geode Capital Management LLCas of 31 Mar 2024 | 13.12k | 0.18% |
| Tower Research Capital LLCas of 31 Mar 2024 | 12.28k | 0.17% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
